Saturday 17 October 2026
Export MBRX’s income statement to Excel — free account
Moleculin Biotech, Inc.
MBRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 95.1% and free cash flow fell 19.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.28
0.09
−24.32%
Follow MBRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
605.39% | (256.84%) | (556.58%) | (1,471.05%) | |
| (269.03%) | (172.41%) | (190.96%) | (152.41%) | ||
ROIC |
0.00% | (256.03%) | (347.23%) | (417.27%) | |
Return on Tangible Assets |
(2,581.01%) | (1,156.84%) | (1,380.58%) | 6,160.04% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(15.05) | (19.19) | (5.89) | (4.46) | |
Free Cash Flow |
(22.45) | (22.73) | (24.28) | (25.36) | |
| Other line items | |||||
Cash ROIC |
111.06% | (95.19%) | (95.22%) | (134.53%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.38 | 0.68 | 0.57 | 0.78 | |
Depreciation/Fixed assets |
1.45 | 1.15 | 0.96 | 0.76 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(15.05) | (19.19) | (5.89) | (4.46) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates